Ata Siddiqui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ata Siddiqui has a total of 279 co-authors. Here are the top co-authors by number of shared publications:
- Ming Lim
Children's Neurosciences Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust London UK
7 shared publications - Steve Connor
Department of Neuroradiology, King’s College Hospital, London, United Kingdom
4 shared publications - David William Carmichael
School of Biomedical Engineering and Imaging Sciences, King’s College London
3 shared publications - Joseph Hajnal
King’s College London
3 shared publications - Katy Vecchiato
King's College London
3 shared publications - Kshitij Mankad
Department of Neuroradiology, Great Ormond Street Hospital NHS Foundation Trust, London, UK
3 shared publications
Latest Publications
- 11 December 2025
- Published by Wiley in Journal of the Peripheral Nervous System
- Vol. 30 (4) , e70088
Impact of High‐Dose Tafamidis on Hereditary ATTR ( ATTRv ) Amyloidosis With Central Nervous System Involvement: Two Case Reports With Clinical, Radiological and Cerebrospinal Fluid Follow Up
Background: Treatment options for central nervous system (CNS) manifestations of ATTRv amyloidosis remain limited, with no disease‐modifying therapy. However, previous case series have indicated that tafamidis (a transthyretin stabiliser) crosses the blood–brain barrier in small quantities. We present long‐term follow‐up data on two patients with CNS manifestations of ATTRv who received high‐dose (61 mg) oral tafamidis. Methods: Patient one is a 48‐year‐old man with p.Gly73Ala ATTRv peripheral neuropathy and commenced on gene‐silencing therapy. He was subsequently diagnosed with early ATTRv CNS involvement, prompting the addition of tafamidis since age 45. Patient two is a 27‐year‐old woman with p.Gly67Arg ATTRv with significant CNS involvement resulting in epilepsy and encephalopathy. Since age 21, she has been on gene‐silencing therapy and tafamidis. Results: Following 3 years of therapy, patient one has remained clinically asymptomatic. However, brain magnetic resonance imaging (MRI) and cerebrospinal fluid assessment have demonstrated progression of his CNS ATTRv. Followed 6 years of therapy, patient two has continued to have seizures requiring escalation of anti‐seizure medications and MRI brain has shown progression of CNS disease. Conclusions: In our two patients, progression of CNS disease occurred whilst on high‐dose tafamidis, highlighting the importance of further studies into the monitoring and treatment of CNS manifestations of ATTRv.
- 11 December 2025
- Published by Wiley in Journal of the Peripheral Nervous System
- Vol. 30 (4) , e70088
Impact of High‐Dose Tafamidis on Hereditary ATTR ( ATTRv ) Amyloidosis With Central Nervous System Involvement: Two Case Reports With Clinical, Radiological and Cerebrospinal Fluid Follow Up
Background: Treatment options for central nervous system (CNS) manifestations of ATTRv amyloidosis remain limited, with no disease‐modifying therapy. However, previous case series have indicated that tafamidis (a transthyretin stabiliser) crosses the blood–brain barrier in small quantities. We present long‐term follow‐up data on two patients with CNS manifestations of ATTRv who received high‐dose (61 mg) oral tafamidis. Methods: Patient one is a 48‐year‐old man with p.Gly73Ala ATTRv peripheral neuropathy and commenced on gene‐silencing therapy. He was subsequently diagnosed with early ATTRv CNS involvement, prompting the addition of tafamidis since age 45. Patient two is a 27‐year‐old woman with p.Gly67Arg ATTRv with significant CNS involvement resulting in epilepsy and encephalopathy. Since age 21, she has been on gene‐silencing therapy and tafamidis. Results: Following 3 years of therapy, patient one has remained clinically asymptomatic. However, brain magnetic resonance imaging (MRI) and cerebrospinal fluid assessment have demonstrated progression of his CNS ATTRv. Followed 6 years of therapy, patient two has continued to have seizures requiring escalation of anti‐seizure medications and MRI brain has shown progression of CNS disease. Conclusions: In our two patients, progression of CNS disease occurred whilst on high‐dose tafamidis, highlighting the importance of further studies into the monitoring and treatment of CNS manifestations of ATTRv.
- Open Access
- 9 September 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (5) , e213921
Ultra-High Field 7T MRI in a Drug-Resistant Pediatric Epilepsy Cohort
Epileptogenic lesions in focal epilepsy can be subtle or remain undetected on conventional MRI. Ultra-high field (7T) MRI offers higher spatial resolution, contrast, and signal-to-noise ratio compared with conventional field strengths and has shown promise in adult presurgical evaluation. However, its utility in pediatric focal epilepsy, where malformations of cortical development are common, remains unclear. In this study, we directly compared 7T and 3T MRI in children with drug-resistant focal epilepsy, evaluating (1) scan tolerability, (2) image quality, and (3) lesion detection yield. In this prospective cohort study, patients were recruited from outpatient clinics at 3 large epilepsy centers in London. Eligible participants were aged 8-17 years and had no contraindications to MRI. Scanning was conducted in 2 separate sessions at 3T and 7T. Safety and tolerability were assessed using age-specific questionnaires and analyzed using the Mann-Whitney test for differences between age groups and the McNemar χ2 test for within-participant cross-field comparisons. Image quality was evaluated by a pediatric neuroradiologist and estimated quantitatively by comparing cortical thickness between field strengths. Lesion detection yield of 7T MRI was assessed by joint review with a multidisciplinary team. A total of 63 children were assessed: 41 patients (mean age 12.6 ± 2.4 years, 22 were male) and 22 healthy controls (8-17 years, mean age 11.7 ± 2.7 years, 15 were male). Both field strengths were well tolerated, and side effects were transient. These included higher dizziness-related discomfort at 7T (p = 0.02, Cohen h = 0.89), with side effects more frequently noted in younger children (scanner noise: p = 0.02, Cohen r = -0.36; metallic taste: p = 0.02, Cohen r = -0.37). Cortical thickness was significantly thinner at 7T for both right (t = 5.65, p < 0.001, Cohen d = -0.72) and left (t = 5.01, p < 0.001, Cohen d = -0.64) hemispheres, with thinner boundaries in temporo-parietal/sensory regions. Although 7T images had increased reported inhomogeneity and artifacts, new lesions were detected in 6 of 26 patients (23%), influencing surgical management in 4 of 26 (15%) (odds ratio 1.86). 7T MRI in children with epilepsy is well tolerated and associated with a 23% improvement in lesion detection, directly affecting clinical management and surgical outcomes. Although limited by a preselected cohort with extensive diagnostic workups, our findings underscore the transformative potential of 7T MRI in presurgical planning for pediatric epilepsy.
- 9 September 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (5) , e213921
Open AccessUltra-High Field 7T MRI in a Drug-Resistant Pediatric Epilepsy Cohort
Epileptogenic lesions in focal epilepsy can be subtle or remain undetected on conventional MRI. Ultra-high field (7T) MRI offers higher spatial resolution, contrast, and signal-to-noise ratio compared with conventional field strengths and has shown promise in adult presurgical evaluation. However, its utility in pediatric focal epilepsy, where malformations of cortical development are common, remains unclear. In this study, we directly compared 7T and 3T MRI in children with drug-resistant focal epilepsy, evaluating (1) scan tolerability, (2) image quality, and (3) lesion detection yield. In this prospective cohort study, patients were recruited from outpatient clinics at 3 large epilepsy centers in London. Eligible participants were aged 8-17 years and had no contraindications to MRI. Scanning was conducted in 2 separate sessions at 3T and 7T. Safety and tolerability were assessed using age-specific questionnaires and analyzed using the Mann-Whitney test for differences between age groups and the McNemar χ2 test for within-participant cross-field comparisons. Image quality was evaluated by a pediatric neuroradiologist and estimated quantitatively by comparing cortical thickness between field strengths. Lesion detection yield of 7T MRI was assessed by joint review with a multidisciplinary team. A total of 63 children were assessed: 41 patients (mean age 12.6 ± 2.4 years, 22 were male) and 22 healthy controls (8-17 years, mean age 11.7 ± 2.7 years, 15 were male). Both field strengths were well tolerated, and side effects were transient. These included higher dizziness-related discomfort at 7T (p = 0.02, Cohen h = 0.89), with side effects more frequently noted in younger children (scanner noise: p = 0.02, Cohen r = -0.36; metallic taste: p = 0.02, Cohen r = -0.37). Cortical thickness was significantly thinner at 7T for both right (t = 5.65, p < 0.001, Cohen d = -0.72) and left (t = 5.01, p < 0.001, Cohen d = -0.64) hemispheres, with thinner boundaries in temporo-parietal/sensory regions. Although 7T images had increased reported inhomogeneity and artifacts, new lesions were detected in 6 of 26 patients (23%), influencing surgical management in 4 of 26 (15%) (odds ratio 1.86). 7T MRI in children with epilepsy is well tolerated and associated with a 23% improvement in lesion detection, directly affecting clinical management and surgical outcomes. Although limited by a preselected cohort with extensive diagnostic workups, our findings underscore the transformative potential of 7T MRI in presurgical planning for pediatric epilepsy.
- Open Access
Mutations in EPG5 are associated with a wide spectrum of neurodevelopmental and neurodegenerative disorders
Autophagy is a fundamental and evolutionary conserved biological pathway with vital roles in intracellular quality control and homeostasis. The process of autophagy involves the engulfment of intracellular targets by autophagosomes and their delivery to the lysosome for digestion and recycling. We have previously reported recessive variants in EPG5 , encoding for the ectopic P-granules 5 autophagy protein with a crucial role in autophagosome-lysosome fusion, as the cause of Vici syndrome (VS), a severe multisystem neurodevelopmental disorder defined by a combination of distinct clinical features including callosal agenesis, cataracts, cardiomyopathy, immunodeficiency, and hypopigmentation. Here, we present extensive novel genetic, clinical, neuroradiological and pathological features from the largest cohort of EPG5 -related disorders reported to date, complemented by experimental findings from patient cells and models of EPG5 defects in Caenorhabditis elegans and Mus musculus . We identified 200 patients with recessive EPG5 variants, 86 of them previously unpublished. The associated phenotypic spectrum ranged from antenatally lethal presentations and the classic VS phenotype (n=60) to much milder neurodevelopmental disorders with less specific manifestations (n=140). Myopathic features and epilepsy with variable progression were frequently observed. Novel manifestations included early-onset parkinsonism and dystonia with cognitive decline during adolescence, hereditary spastic paraplegia (HSPP), and myoclonus. Radiological findings included previously recognized EPG5 -related features with callosal abnormalities and pontocerebellar hypoplasia, and a range of novel features suggesting an emerging continuum with disorders of brain iron accumulation or copper metabolism as well as HSPPs. Genotype-phenotype studies suggested a correlation between predicted residual EPG5 expression and clinical severity, especially regarding disease progression and survival. The Epg5 p.Gln331Arg knock-in mouse, a model of milder EPG5 -related disorders, showed an age-related motor phenotype and impaired autophagic clearance in several brain regions mirroring those also affected in humans. In Caenorhabditis elegans, epg-5 knockdown gave rise to neurodevelopmental features and motor impairment comparable to defects in parkinsonism-related genes, abnormal mitochondrial respiration, and impaired mitophagic clearance early in life. Cellular assays revealed impaired PINK1-Parkin dependent mitophagic clearance in patient fibroblasts. Our findings expand the phenotypic spectrum of EPG5 -related disorders and indicate a life time continuum of disease that overlaps with other disorders of defective autophagy and intracellular trafficking. Our observations also suggest close links between early-onset neurodevelopmental and neurodegenerative conditions of later onset due to EPG5 defects, in particular dystonia and parkinsonism, highlighting the fundamental importance of dysfunctional autophagy in the pathophysiology of common neurodegenerative disorders.
Open AccessMutations in EPG5 are associated with a wide spectrum of neurodevelopmental and neurodegenerative disorders
Autophagy is a fundamental and evolutionary conserved biological pathway with vital roles in intracellular quality control and homeostasis. The process of autophagy involves the engulfment of intracellular targets by autophagosomes and their delivery to the lysosome for digestion and recycling. We have previously reported recessive variants in EPG5 , encoding for the ectopic P-granules 5 autophagy protein with a crucial role in autophagosome-lysosome fusion, as the cause of Vici syndrome (VS), a severe multisystem neurodevelopmental disorder defined by a combination of distinct clinical features including callosal agenesis, cataracts, cardiomyopathy, immunodeficiency, and hypopigmentation. Here, we present extensive novel genetic, clinical, neuroradiological and pathological features from the largest cohort of EPG5 -related disorders reported to date, complemented by experimental findings from patient cells and models of EPG5 defects in Caenorhabditis elegans and Mus musculus . We identified 200 patients with recessive EPG5 variants, 86 of them previously unpublished. The associated phenotypic spectrum ranged from antenatally lethal presentations and the classic VS phenotype (n=60) to much milder neurodevelopmental disorders with less specific manifestations (n=140). Myopathic features and epilepsy with variable progression were frequently observed. Novel manifestations included early-onset parkinsonism and dystonia with cognitive decline during adolescence, hereditary spastic paraplegia (HSPP), and myoclonus. Radiological findings included previously recognized EPG5 -related features with callosal abnormalities and pontocerebellar hypoplasia, and a range of novel features suggesting an emerging continuum with disorders of brain iron accumulation or copper metabolism as well as HSPPs. Genotype-phenotype studies suggested a correlation between predicted residual EPG5 expression and clinical severity, especially regarding disease progression and survival. The Epg5 p.Gln331Arg knock-in mouse, a model of milder EPG5 -related disorders, showed an age-related motor phenotype and impaired autophagic clearance in several brain regions mirroring those also affected in humans. In Caenorhabditis elegans, epg-5 knockdown gave rise to neurodevelopmental features and motor impairment comparable to defects in parkinsonism-related genes, abnormal mitochondrial respiration, and impaired mitophagic clearance early in life. Cellular assays revealed impaired PINK1-Parkin dependent mitophagic clearance in patient fibroblasts. Our findings expand the phenotypic spectrum of EPG5 -related disorders and indicate a life time continuum of disease that overlaps with other disorders of defective autophagy and intracellular trafficking. Our observations also suggest close links between early-onset neurodevelopmental and neurodegenerative conditions of later onset due to EPG5 defects, in particular dystonia and parkinsonism, highlighting the fundamental importance of dysfunctional autophagy in the pathophysiology of common neurodegenerative disorders.
- 6 September 2023
- Published by Springer Nature in Pediatric Radiology
- Vol. 53 (12) , 2323-2344
Recommendations for neuroradiological examinations in children living with achondroplasia: a European Society of Pediatric Radiology and European Society of Neuroradiology opinion paper
Children living with achondroplasia are at an increased risk of developing neurological complications, which may be associated with acute and life-altering events. To remediate this risk, the timely acquisition of effective neuroimaging that can help to guide clinical management is essential. We propose imaging protocols and follow-up strategies for evaluating the neuroanatomy of these children and to effectively identify potential neurological complications, including compression at the cervicomedullary junction secondary to foramen magnum stenosis, spinal deformity and spinal canal stenosis. When compiling these recommendations, emphasis has been placed on reducing scan times and avoiding unnecessary radiation exposure. Standardized imaging protocols are important to ensure that clinically useful neuroimaging is performed in children living with achondroplasia and to ensure reproducibility in future clinical trials. The members of the European Society of Pediatric Radiology (ESPR) Neuroradiology Taskforce and European Society of Neuroradiology pediatric subcommittee, together with clinicians and surgeons with specific expertise in achondroplasia, wrote this opinion paper. The research committee of the ESPR also endorsed the final draft. The rationale for these recommendations is based on currently available literature, supplemented by best practice opinion from radiologists and clinicians with subject-specific expertise. Graphical Abstract
- 6 September 2023
- Published by Springer Nature in Pediatric Radiology
- Vol. 53 (12) , 2323-2344
Recommendations for neuroradiological examinations in children living with achondroplasia: a European Society of Pediatric Radiology and European Society of Neuroradiology opinion paper
Children living with achondroplasia are at an increased risk of developing neurological complications, which may be associated with acute and life-altering events. To remediate this risk, the timely acquisition of effective neuroimaging that can help to guide clinical management is essential. We propose imaging protocols and follow-up strategies for evaluating the neuroanatomy of these children and to effectively identify potential neurological complications, including compression at the cervicomedullary junction secondary to foramen magnum stenosis, spinal deformity and spinal canal stenosis. When compiling these recommendations, emphasis has been placed on reducing scan times and avoiding unnecessary radiation exposure. Standardized imaging protocols are important to ensure that clinically useful neuroimaging is performed in children living with achondroplasia and to ensure reproducibility in future clinical trials. The members of the European Society of Pediatric Radiology (ESPR) Neuroradiology Taskforce and European Society of Neuroradiology pediatric subcommittee, together with clinicians and surgeons with specific expertise in achondroplasia, wrote this opinion paper. The research committee of the ESPR also endorsed the final draft. The rationale for these recommendations is based on currently available literature, supplemented by best practice opinion from radiologists and clinicians with subject-specific expertise. Graphical Abstract
- 23 April 2022
- Published by Springer Nature in Neuroradiology
- Vol. 64 (6) , 1081-1100
Guidelines for magnetic resonance imaging in pediatric head and neck pathologies: a multicentre international consensus paper
The use of standardized imaging protocols is paramount in order to facilitate comparable, reproducible images and, consequently, to optimize patient care. Standardized MR protocols are lacking when studying head and neck pathologies in the pediatric population. We propose an international, multicenter consensus paper focused on providing the best combination of acquisition time/technical requirements and image quality. Distinct protocols for different regions of the head and neck and, in some cases, for specific pathologies or clinical indications are recommended. This white paper is endorsed by several international scientific societies and it is the result of discussion, in consensus, among experts in pediatric head and neck imaging.
- 23 April 2022
- Published by Springer Nature in Neuroradiology
- Vol. 64 (6) , 1081-1100
Guidelines for magnetic resonance imaging in pediatric head and neck pathologies: a multicentre international consensus paper
The use of standardized imaging protocols is paramount in order to facilitate comparable, reproducible images and, consequently, to optimize patient care. Standardized MR protocols are lacking when studying head and neck pathologies in the pediatric population. We propose an international, multicenter consensus paper focused on providing the best combination of acquisition time/technical requirements and image quality. Distinct protocols for different regions of the head and neck and, in some cases, for specific pathologies or clinical indications are recommended. This white paper is endorsed by several international scientific societies and it is the result of discussion, in consensus, among experts in pediatric head and neck imaging.
- Open Access
Acute Myelopathy in Childhood
Acute myelopathy presenting in childhood can be clinically classified based on the location of injury (with resulting spinal syndrome) or the cause (broadly traumatic or non-traumatic). Types of nontraumatic myelopathy include ischaemic, infectious, inflammatory, nutritional, and metabolic causes, some of which may be part of a systemic illness such as systemic lupus erythematosus or a demyelinating disease such as multiple sclerosis. Nonaccidental injury is an important consideration in cases of traumatic myelopathy, which may often be associated with other injuries. Assessment should include neuroimaging of the brain and spinal cord, with further investigations targeted based on the most likely differential diagnoses; for example, a child with suspected demyelinating disease may require specialist cerebrospinal fluid and serological testing. Management also will differ based on the cause of the myelopathy, with several of these treatments more efficacious with earlier initiation, necessitating prompt recognition, diagnosis, and treatment of children presenting with symptoms of a myelopathy. Important components of holistic care may include physiotherapy and occupational therapy, with multidisciplinary team involvement as required (for example psychological support or specialist bowel and bladder teams).
Open AccessAcute Myelopathy in Childhood
Acute myelopathy presenting in childhood can be clinically classified based on the location of injury (with resulting spinal syndrome) or the cause (broadly traumatic or non-traumatic). Types of nontraumatic myelopathy include ischaemic, infectious, inflammatory, nutritional, and metabolic causes, some of which may be part of a systemic illness such as systemic lupus erythematosus or a demyelinating disease such as multiple sclerosis. Nonaccidental injury is an important consideration in cases of traumatic myelopathy, which may often be associated with other injuries. Assessment should include neuroimaging of the brain and spinal cord, with further investigations targeted based on the most likely differential diagnoses; for example, a child with suspected demyelinating disease may require specialist cerebrospinal fluid and serological testing. Management also will differ based on the cause of the myelopathy, with several of these treatments more efficacious with earlier initiation, necessitating prompt recognition, diagnosis, and treatment of children presenting with symptoms of a myelopathy. Important components of holistic care may include physiotherapy and occupational therapy, with multidisciplinary team involvement as required (for example psychological support or specialist bowel and bladder teams).
- 5 August 2021
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 42 (10) , 1898-1903
Persistent Trigeminal Artery: A Novel Imaging Finding in CHARGE Syndrome
BACKGROUND AND PURPOSE: Coloboma of the eye, Heart defects, Atresia of the choanae, Retardation of growth and/or development, Genital and/or urinary abnormalities, Ear abnormalities and deafness (CHARGE) syndrome is an autosomal dominant genetic disorder with evolving clinical diagnostic criteria. Recently, a number of additional anomalies have been described in this syndrome, which may aid in early diagnosis, particularly in incomplete phenotypes or atypical cases. The persistent trigeminal artery is an embryonic carotid-vertebral anastomosis, rarely seen in the healthy population, with a reported prevalence of 0.4%. Because we had observed the persistent trigeminal artery in patients with CHARGE syndrome, this study aimed to explore the prevalence of the persistent trigeminal artery in this syndrome. MATERIALS AND METHODS: A retrospective study was performed at our tertiary center. MR imaging studies, clinical records, and genetic results were reviewed for patients diagnosed with CHARGE syndrome between 2006 and 2019. The prevalence of the persistent trigeminal artery in patients with CHARGE syndrome was recorded and compared with other established diagnostic criteria. RESULTS: Twenty-five patients with CHARGE syndrome were included. The persistent trigeminal artery was demonstrated on MR imaging in 14/25 (56%) patients and was seen more frequently than 4 of 9 other established diagnostic criteria in our cohort. When individual major or minor diagnostic criteria were absent, the persistent trigeminal artery was still demonstrated on MR imaging in 52%–67% of these patients with CHARGE syndrome. CONCLUSIONS: The prevalence of the persistent trigeminal artery in CHARGE syndrome of 56% is higher than that of some other established diagnostic criteria and much higher than that in the general population. The persistent trigeminal artery may be a useful addition to the expanding phenotype of CHARGE syndrome, supplementing other diagnostic criteria. Radiologists should be aware of this novel finding demonstrable on MR imaging.
- 5 August 2021
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 42 (10) , 1898-1903
Persistent Trigeminal Artery: A Novel Imaging Finding in CHARGE Syndrome
BACKGROUND AND PURPOSE: Coloboma of the eye, Heart defects, Atresia of the choanae, Retardation of growth and/or development, Genital and/or urinary abnormalities, Ear abnormalities and deafness (CHARGE) syndrome is an autosomal dominant genetic disorder with evolving clinical diagnostic criteria. Recently, a number of additional anomalies have been described in this syndrome, which may aid in early diagnosis, particularly in incomplete phenotypes or atypical cases. The persistent trigeminal artery is an embryonic carotid-vertebral anastomosis, rarely seen in the healthy population, with a reported prevalence of 0.4%. Because we had observed the persistent trigeminal artery in patients with CHARGE syndrome, this study aimed to explore the prevalence of the persistent trigeminal artery in this syndrome. MATERIALS AND METHODS: A retrospective study was performed at our tertiary center. MR imaging studies, clinical records, and genetic results were reviewed for patients diagnosed with CHARGE syndrome between 2006 and 2019. The prevalence of the persistent trigeminal artery in patients with CHARGE syndrome was recorded and compared with other established diagnostic criteria. RESULTS: Twenty-five patients with CHARGE syndrome were included. The persistent trigeminal artery was demonstrated on MR imaging in 14/25 (56%) patients and was seen more frequently than 4 of 9 other established diagnostic criteria in our cohort. When individual major or minor diagnostic criteria were absent, the persistent trigeminal artery was still demonstrated on MR imaging in 52%–67% of these patients with CHARGE syndrome. CONCLUSIONS: The prevalence of the persistent trigeminal artery in CHARGE syndrome of 56% is higher than that of some other established diagnostic criteria and much higher than that in the general population. The persistent trigeminal artery may be a useful addition to the expanding phenotype of CHARGE syndrome, supplementing other diagnostic criteria. Radiologists should be aware of this novel finding demonstrable on MR imaging.
- Open Access
- 1 July 2021
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 8 (4)
Systemic Inflammation Is Associated With Neurologic Involvement in Pediatric Inflammatory Multisystem Syndrome Associated With SARS-CoV-2
Objective Pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) is a severe immune-mediated disorder. We aim to report the neurologic features of children with PIMS-TS. Methods We identified children presenting to a large children9s hospital with PIMS-TS from March to June 2020 and performed a retrospective medical note review, identifying clinical and investigative features alongside short-term outcome of children presenting with neurologic symptoms. Results Seventy-five patients with PIMS-TS were identified, 9 (12%) had neurologic involvement: altered conciseness (3), behavioral changes (3), focal neurology deficits (2), persistent headaches (2), hallucinations (2), excessive sleepiness (1), and new-onset focal seizures (1). Four patients had cranial images abnormalities. At 3-month follow-up, 1 child had died, 1 had hemiparesis, 3 had behavioral changes, and 4 completely recovered. Systemic inflammatory and prothrombotic markers were higher in patients with neurologic involvement (mean highest CRP 267 vs 202 mg/L, p = 0.05; procalcitonin 30.65 vs 13.11 μg/L, p = 0.04; fibrinogen 7.04 vs 6.17 g/L, p = 0.07; d-dimers 19.68 vs 7.35 mg/L, p = 0.005). Among patients with neurologic involvement, these markers were higher in those without full recovery at 3 months (ferritin 2284 vs 283 μg/L, p = 0.05; d-dimers 30.34 vs 6.37 mg/L, p = 0.04). Patients with and without neurologic involvement shared similar risk factors for PIMS-TS (Black, Asian and Minority Ethnic ethnicity 78% vs 70%, obese/overweight 56% vs 42%). Conclusions Broad neurologic features were found in 12% patients with PIMS-TS. By 3-month follow-up, half of these surviving children had recovered fully without neurologic impairment. Significantly higher systemic inflammatory markers were identified in children with neurologic involvement and in those who had not recovered fully.
- 1 July 2021
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 8 (4)
Open AccessSystemic Inflammation Is Associated With Neurologic Involvement in Pediatric Inflammatory Multisystem Syndrome Associated With SARS-CoV-2
Objective Pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) is a severe immune-mediated disorder. We aim to report the neurologic features of children with PIMS-TS. Methods We identified children presenting to a large children9s hospital with PIMS-TS from March to June 2020 and performed a retrospective medical note review, identifying clinical and investigative features alongside short-term outcome of children presenting with neurologic symptoms. Results Seventy-five patients with PIMS-TS were identified, 9 (12%) had neurologic involvement: altered conciseness (3), behavioral changes (3), focal neurology deficits (2), persistent headaches (2), hallucinations (2), excessive sleepiness (1), and new-onset focal seizures (1). Four patients had cranial images abnormalities. At 3-month follow-up, 1 child had died, 1 had hemiparesis, 3 had behavioral changes, and 4 completely recovered. Systemic inflammatory and prothrombotic markers were higher in patients with neurologic involvement (mean highest CRP 267 vs 202 mg/L, p = 0.05; procalcitonin 30.65 vs 13.11 μg/L, p = 0.04; fibrinogen 7.04 vs 6.17 g/L, p = 0.07; d-dimers 19.68 vs 7.35 mg/L, p = 0.005). Among patients with neurologic involvement, these markers were higher in those without full recovery at 3 months (ferritin 2284 vs 283 μg/L, p = 0.05; d-dimers 30.34 vs 6.37 mg/L, p = 0.04). Patients with and without neurologic involvement shared similar risk factors for PIMS-TS (Black, Asian and Minority Ethnic ethnicity 78% vs 70%, obese/overweight 56% vs 42%). Conclusions Broad neurologic features were found in 12% patients with PIMS-TS. By 3-month follow-up, half of these surviving children had recovered fully without neurologic impairment. Significantly higher systemic inflammatory markers were identified in children with neurologic involvement and in those who had not recovered fully.
- 18 February 2021
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 42 (4) , 774-781
Evaluation of DISORDER: Retrospective Image Motion Correction for Volumetric Brain MRI in a Pediatric Setting
Many claims are made for the power of prayer, but the idea that it could work retrospectively has caused considerable controversy. It is also beyond current scientific knowledge
- 18 February 2021
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 42 (4) , 774-781
Evaluation of DISORDER: Retrospective Image Motion Correction for Volumetric Brain MRI in a Pediatric Setting
Many claims are made for the power of prayer, but the idea that it could work retrospectively has caused considerable controversy. It is also beyond current scientific knowledge
- Open Access
Idiopathic Hypertrophic Pachymeningitis: Does Earlier Treatment Improve Outcome?
Background/goal: Hypertrophic pachymeningitis is a rare chronic inflammatory disorder characterized by marked fibrous thickening of the cerebral and/or spinal dura mater. This condition has largely been reported in adults, but there are very few reports in children. Methods: We describe a 14-year-old boy with idiopathic hypertrophic pachymeningitis, who presented with deteriorating vision on a background of severe headache. We evaluated pediatric cases of hypertrophic pachymeningitis and compared treatments and their relation to outcomes. Results: There are only eleven pediatric cases of hypertrophic pachymeningitis reported in the literature. In the patients treated with steroids either at presentation or subsequent relapses, a good response was reported. In the cases with delayed initiation of steroid treatment, this was often related to an incomplete recovery. In our patient, this delay may have contributed to his poor visual outcome. Conclusions: Early initiation of steroid treatment in children with idiopathic hypertrophic pachymeningitis may improve outcomes.
Open AccessIdiopathic Hypertrophic Pachymeningitis: Does Earlier Treatment Improve Outcome?
Background/goal: Hypertrophic pachymeningitis is a rare chronic inflammatory disorder characterized by marked fibrous thickening of the cerebral and/or spinal dura mater. This condition has largely been reported in adults, but there are very few reports in children. Methods: We describe a 14-year-old boy with idiopathic hypertrophic pachymeningitis, who presented with deteriorating vision on a background of severe headache. We evaluated pediatric cases of hypertrophic pachymeningitis and compared treatments and their relation to outcomes. Results: There are only eleven pediatric cases of hypertrophic pachymeningitis reported in the literature. In the patients treated with steroids either at presentation or subsequent relapses, a good response was reported. In the cases with delayed initiation of steroid treatment, this was often related to an incomplete recovery. In our patient, this delay may have contributed to his poor visual outcome. Conclusions: Early initiation of steroid treatment in children with idiopathic hypertrophic pachymeningitis may improve outcomes.